A Survivorship Care Plan and Embedded Navigation Tool



Status:Recruiting
Conditions:Prostate Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:2/3/2019
Start Date:January 11, 2019
End Date:January 2023
Contact:Andrew Peterson, M.D.
Email:drew.peterson@duke.edu
Phone:919-684-2516

Use our guide to learn which trials are right for you!

Evaluation of the Impact of A Survivorship Care Plan and Embedded Navigation Tool (ASCENT) in Patients With Prostate Cancer Undergoing Curative-Intent Radiotherapy With Concurrent Androgen Deprivation Therapy (ADT)

This is a parallel group, multisite prospective clinical study. The purpose of this study is
to evaluate whether ASCENT enables patients to adhere to the survivorship guidelines and
improves coordination of care to address patient needs.


Inclusion Criteria:

- Histologically confirmed diagnosis of prostate adenocarcinoma

- Age ≥18 years

- Receiving curative intent radiotherapy for prostate cancer (Note: post-operative
radiotherapy [i.e., "adjuvant" or "salvage radiotherapy subsequent to prostatectomy]
is allowed.)

- Subjects will be enrolled within two weeks prior to and two weeks after the final
fraction of radiotherapy.

- Receiving androgen deprivation therapy (ADT) for a duration of ≥3 consecutive months
as follows:

- GnRH agonist or antagonist (medical castration), with or without an anti-androgen
(i.e., bicalutamide, flutamide, nilutamide, etc.), OR

- Bilateral orchiectomy (surgical castration)

- Technology requirement: candidates must have access to the internet

- Able to understand and willing to sign a written informed consent document.

- Able to speak and understand English, in the opinion of the treating physician.

Exclusion Criteria:

- Significant concurrent medical or psychiatric condition that would interfere with the
patient's ability to abide by the study protocol or cooperate fully with the protocol
requirements, including completion of survey and assessment
We found this trial at
7
sites
450 West Drive
Chapel Hill, North Carolina 27599
Principal Investigator: Ronald Chen, M.D.
Phone: 984-974-8428
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
12902 USF Magnolia Dr
Tampa, Florida 33612
(888) 663-3488
Principal Investigator: Kosj Yamoah, M.D.
Phone: 813-745-8343
H. Lee Moffitt Cancer Center & Research Institute Moffitt Cancer Center in Tampa, Florida, has...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Pretesh Patel, M.D.
Phone: 404-778-4617
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Baltimore, Maryland 21205
Principal Investigator: Craig Pollack, M.D., MHS
Phone: 410-502-2359
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Ann Partridge, MD
Phone: 617-632-5592
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
20 Duke Clinic Cir
Durham, North Carolina 27710
(888) 275-3853
Principal Investigator: Andrew Peterson, M.D.
Phone: 919-668-2314
Duke Cancer Institute Leading-edge cancer care and research have been a hallmark of Duke Medicine...
?
mi
from
Durham, NC
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Sigrid Carlsson, M.D.,PhD, MPH
Phone: 646-888-8269
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials